Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

FFF Enterprises Announces New Flu Vaccine Available for Immediate Shipment Leading Flu Vaccine Distributor Offers Recently Approved Single-Dose Vials of Flublok(R), the World's First Recombinant, Highly-Purified, Egg-Free Influenza Vaccine


Print article Print article
© Marketwire 2013
2013-02-13 18:34:01 -

TEMECULA, CA -- (Marketwire) -- 02/13/13 -- In response to the country's continuing flu epidemic in the West and Southwest, FFF Enterprises announced today that single-dose vials of the newly FDA-approved Flublok influenza vaccine are available for shipment.



"FFF is always prepared to respond to the unpredictable nature of flu season -- including the current late season epidemic. The big message is that it is not too late to vaccinate and we have a selection of vaccines available for shipment, including Flublok," said Patrick M. Schmidt, chief executive officer, FFF Enterprises, Inc. "Flublok represents an important addition to our extensive flu vaccine portfolio."





Flublok, a recombinant, egg-free formulation manufactured by Protein Sciences Corporation, Inc., was just approved by the FDA for ages 18-49 in January 2013. Approval for all adults 18 and older is expected later this year. Flublok is highly purified, has three times the amount of active ingredient in traditional influenza vaccines, and contains no preservatives (thimerosal), antibiotics, latex, or adjuvants.



"Flublok is truly a breakthrough vaccine," said Manon Cox, chief executive officer, Protein Sciences Corporation. "We use advanced scientific technology to make the active ingredient of the vaccine without any other viral components. This is the first influenza vaccine on the market to do so. We are also the first to make an influenza vaccine using a completely egg-free process."



About FFF Enterprises, Inc.
Temecula-based FFF Enterprises is the largest and most trusted distributor of plasma products, vaccines and other biopharmaceuticals in the U.S. Founded in 1988, FFF is now in its 25th year with more than a billion dollars in annual sales and a flawless safety track record. FFF has taken a leadership position in regard to supply chain safety and innovation, setting new standards and pioneering industry firsts. FFF's commitment to Guaranteed Channel Integrity™ ensures that products are purchased only from the manufacturer and shipped only to healthcare providers, with additional steps taken to safely store, handle and ship products to ensure patient safety is never compromised. FFF's proprietary systems, Verified Electronic Pedigree™ and Lot-Track™, provide verification of this secure channel, and FFF's MyFluVaccine ( www.MyFluVaccine.com : ctt.marketwire.com/?release=985521&id=2612704&type=1& .. ) and VaxAmerica ( www.VaxAmerica.com : ctt.marketwire.com/?release=985521&id=2612707&type=1& .. ) are revolutionary vaccination programs that have added a new level of safety, convenience and reliability to both healthcare providers and consumers.



About Protein Sciences Corporation
Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT. The Company is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. Its proprietary BEVS technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most. BEVS technology is covered by broad patents that include the Company's proprietary expresSF+® cell line it uses to make all of the Company's products. Protein Sciences recently expanded to Pearl River, NY, where it will manufacture Flublok in addition to its Meriden, CT facility. Learn more at www.flublok.com : ctt.marketwire.com/?release=985521&id=2612710&type=1& .. and www.proteinsciences.com : ctt.marketwire.com/?release=985521&id=2612713&type=1& .. .




Contact:
Sue Richter
VP of Marketing and Communications
(951) 296-2500, ext. 1357



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com